Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHD - Episode 4

Role of Ruxolitinib in Steroid-Refractory Chronic GvHD

,

Dr. Chaudhary introduces data supporting the use of ruxolitinib as a first-line option in patients with steroid-refractory chronic GvHD.

EP. 1: The Chronic GvHD Landscape: Risk Factors and Diagnosis
EP. 2: First-line Treatment for Patients with Chronic GvHD
EP. 3: Defining and Managing Steroid Refractory Chronic GvHD
Now Viewing
EP. 4: Role of Ruxolitinib in Steroid-Refractory Chronic GvHD
EP. 5: Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil
EP. 6: Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients
EP. 7: Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD
EP. 8: Future Directions in Chronic GvHD

Related Content:

Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHDOncLive News Network®
Key Takeaways for Concurrent Biomarker Testing in NSCLC
Overcoming Barriers to NSCLC Biomarker Testing
Challenges of NSCLC Biomarker Testing in Clinical Practice